193 related articles for article (PubMed ID: 38326166)
1. JAK inhibitors for the treatment of vitiligo.
Inoue S; Suzuki T; Sano S; Katayama I
J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
[TBL] [Abstract][Full Text] [Related]
2. This Month in JAAD International: December 2022: Topical management of vitiligo with Janus kinase inhibitors.
Kantor J
J Am Acad Dermatol; 2022 Dec; 87(6):1284. PubMed ID: 36228949
[No Abstract] [Full Text] [Related]
3. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
4. Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N; Turchin I
Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
[TBL] [Abstract][Full Text] [Related]
5. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
6. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo.
Iwanowski T; Kołkowski K; Nowicki RJ; Sokołowska-Wojdyło M
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298700
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
Dogra S; Sharma A; Mehta H; Sarkar R
Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
Sardana K; Muddebihal A; Khurana A
Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
[TBL] [Abstract][Full Text] [Related]
9. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
10. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
Relke N; Gooderham M
J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the treatment of vitiligo.
Karagaiah P; Valle Y; Sigova J; Zerbinati N; Vojvodic P; Parsad D; Schwartz RA; Grabbe S; Goldust M; Lotti T
Expert Opin Emerg Drugs; 2020 Mar; 25(1):7-24. PubMed ID: 31958256
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K; Peeva E; Yamaguchi Y; Cox LA; Banerjee A; Han G; Hamzavi I; Ganesan AK; Picardo M; Thaçi D; Harris JE; Bae JM; Tsukamoto K; Sinclair R; Pandya AG; Sloan A; Yu D; Gandhi K; Vincent MS; King B
J Am Acad Dermatol; 2023 Feb; 88(2):395-403. PubMed ID: 36370907
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
14. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
Phan K; Phan S; Shumack S; Gupta M
J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
[TBL] [Abstract][Full Text] [Related]
15. Topical ruxolitinib: A new treatment for vitiligo.
Tavoletti G; Avallone G; Conforti C; Roccuzzo G; Maronese CA; Mattioli MA; Quaglino P; Zalaudek I; Marzano AV; Ribero S; Alberti-Violetti S
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2222-2230. PubMed ID: 37147856
[TBL] [Abstract][Full Text] [Related]
16. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
Grossmann MC; Haidari W; Feldman SR
J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
[TBL] [Abstract][Full Text] [Related]
17. Topical Janus kinase inhibitors: A review of applications in dermatology.
Hosking AM; Juhasz M; Mesinkovska NA
J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
[TBL] [Abstract][Full Text] [Related]
18. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Niu C; Xie H; Aisa HA
Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
[TBL] [Abstract][Full Text] [Related]
19. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
20. Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.
Guttman-Yassky E; Del Duca E; Da Rosa JC; Bar J; Ezzedine K; Ye Z; He W; Hyde C; Hassan-Zahraee M; Yamaguchi Y; Peeva E
J Allergy Clin Immunol; 2024 Jan; 153(1):161-172.e8. PubMed ID: 37777018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
